Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Gemcitabine in Advanced sRCC
NCT03483883Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2018
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in renal cell carcinoma (RCC), sponsored by Abramson Cancer Center. Primary endpoint: Adverse Events at 36 months. Started Mar 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03483883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483883.